Xeris Biopharma Holdings, Inc. (XERS) Stock Price & Analysis

Xeris Biopharma Holdings, Inc. (XERS) fell 0.70% to USD 8.53 as of September 8, 2026 at 07:35 UTC, according to Nexqual real-time market data.

XERS last closed at USD 8.53; the session ranged USD 8.39–8.59 on volume of 1,030,533 shares. Market capitalization is —, with a 52-week range of USD 5.25–10.08 (NMS). Source: Nexqual, September 8, 2026 at 07:35 UTC.

Key Statistics (as of September 8, 2026 at 07:35 UTC)

Technical Analysis (XERS)

Nexqual's technical model rates XERS "BUY" based on 4 bullish and 1 bearish signals across 128 daily candles, as of September 8, 2026 at 07:35 UTC.

From Xeris Biopharma Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)

Key Strengths & Strategy (as disclosed to the SEC)

• Included in the total patents, we have 69 granted patents globally related to our platform technologies, and 5 patents granted and in force in the United States and listed in the United States Food and Drug Administration ("FDA") Orange Book covering proprietary formulations of levoketoconazole (the active pharmaceutical ingredient in Recorlev) and the uses of such formulations in treating certain endocrine-related diseases and syndromes.
• We are advancing our Phase 3-ready pipeline product, XP-8121, once-weekly subcutaneous ("SC") levothyroxine, which leverages our proprietary technology XeriSol.
• We believe this therapy represents a significant commercial opportunity in the United States, with the potential to generate approximately $1 billion in annual net revenue at peak penetration. • Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia.
• The estimated total addressable market for this therapy is 3-5 million patients or more in the United States which we estimate is a $1.0 to $3.0 billion peak net sales opportunity. • Partnerships: We are pursuing formulation and development partnerships to apply our XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies' proprietary drugs and biologics.

Partnerships

• We have entered into a non-exclusive supply agreement with Bachem.
• We have entered into a non-exclusive supply agreement with Pyramid.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:35 UTC. This page is informational and not investment advice.